Clinical trial
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell…
NCT00076011 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00076011 |
|---|---|
| Title | Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma |
| Official title | Phase 2 Study of AG 013736 as Second-Line Treatment in Patients With Metastatic Renal Cell Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Neoplasms |
| Intervention type | Drug |
| Interventions | Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor |
| Enrollment | 52 |
| Start date | Oct 1, 2003 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Jan 14, 2004 |
| Last update posted | Jun 26, 2012 |
| Countries | France, Germany, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: